Coloplast

coloplast.com

Coloplast develops products and services to make life easier for people with deeply personal and private medical conditions. These conditions are often associated with trauma and taboo. The more intimate the condition, the greater the requirement to come closer to customers, understand their world and develop solutions that are sensitive to their special needs. We call this Intimate Healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

CORDENPHARMA COMPLETES ACQUISITION OF THREE MANUFACTURING FACILITIES FROM VIFOR PHARMA

CordenPharma | February 01, 2022

news image

CordenPharma, a leading, full-service Contract Development & Manufacturing Organization supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. in Switzerland, and Corden Pharma Lisbon S.A. in Portugal. "We welcome the three sites and their employees as new members to the Cor...

Read More

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

news image

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More

RESEARCH

PFIZER, MODERNA URGE CALM AS THEY LAUNCH TESTS OF VACCINES AGAINST MUTATED COVID-19

Pfizer | December 29, 2020

news image

After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection? Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fig...

Read More

BUSINESS INSIGHTS

KARO PHARMA ACQUIRES OTC BRAND PORTFOLIO FROM TEVA PHARMACEUTICALS

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

news image

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 202...

Read More
news image

BUSINESS INSIGHTS

CORDENPHARMA COMPLETES ACQUISITION OF THREE MANUFACTURING FACILITIES FROM VIFOR PHARMA

CordenPharma | February 01, 2022

CordenPharma, a leading, full-service Contract Development & Manufacturing Organization supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. in Switzerland, and Corden Pharma Lisbon S.A. in Portugal. "We welcome the three sites and their employees as new members to the Cor...

Read More
news image

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More
news image

RESEARCH

PFIZER, MODERNA URGE CALM AS THEY LAUNCH TESTS OF VACCINES AGAINST MUTATED COVID-19

Pfizer | December 29, 2020

After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection? Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fig...

Read More
news image

BUSINESS INSIGHTS

KARO PHARMA ACQUIRES OTC BRAND PORTFOLIO FROM TEVA PHARMACEUTICALS

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 202...

Read More

Resources

resource image

BUSINESS INSIGHTS, PHARMA TECH

West Pharmaceutical Services

Video

resource image

BUSINESS INSIGHTS, VIEWS AND ANALYSIS

Asia Pacific – Clinical trial landscape

Whitepaper

resource image

BUSINESS INSIGHTS, PHARMA TECH

West Pharmaceutical Services

Video

resource image

BUSINESS INSIGHTS, VIEWS AND ANALYSIS

Asia Pacific – Clinical trial landscape

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us